吡嗪酰胺介入凝胶体外抗结核活性及临床应用  

Antibuberculosis activity and clinical efficacy of pyrazinamide gel intervention

作　　者：李洪敏[1] 冯端浩[1] 王巍[1] 金关甫[1] 徐燕杰[1] 林明贵[1] 刘振平[1] 张涛[1] 王金河[1] 高杉[1] 

机构地区：[1]解放军第309医院,北京市100091

出　　处：《中国抗生素杂志》2004年第12期757-759,共3页Chinese Journal of Antibiotics

基　　金：首都医学发展科研基金项目(2002~3016)

摘　　要：目的观察吡嗪酰胺凝胶体外抗结核作用和支气管介入的安全性。方法手工法、仪器法分别测定吡嗪酰胺单体、吡嗪酰胺凝胶的最小抑菌浓度(MIC)和最小杀菌浓度(MBC)及家兔经支气管介入的安全性试验。结果吡嗪酰胺凝胶对人型结核分枝杆菌标准株、牛型结核分枝杆菌、草分枝杆菌MIC值分别为1.0、1.0、10mg/L,MBC值分别为10、10、40mg/L;吡嗪酰胺凝胶与吡嗪酰胺单体MIC、MBC值无显著性差异;动物安全性试验阴性。结论吡嗪酰胺凝胶具有与吡嗪酰胺单体相同的抗结核菌药效,卡波姆基质不影响吡嗪酰胺的抗菌活性;卡波姆基质吡嗪酰胺凝胶应用安全。Objective To observe the activity of pyrazinamide gel against Mycobacterium tuberculosis in vitro and its security in bronchial interventional therapy. Methods The MIC and MBC of pyrazinamide and pyrazinamide gel were measured by mannual method and instrument method and the safety of pyrazinamide gel was assessed by bronchial interventional therapy in rabbits. Results The MICs of pyrazinamide gel to ~M.tuberculosis H37Rv, M.bovis and M.phlei were 1mg/L, 1mg/L and 10mg/L; the MBCs of pyrazinamide gel to M.tuberculosis H37Rv, M.bovis and M.phlei were 10mg/L, 10mg/L and 40mg/L respectively; the MIC and MBC of pyrazinamide gel and those of pyrazinamide had no significant differences; the animal safety experiment was negative. Conclusion These results suggest that pyrazinamide gel and pyrazinamide have the same efficacy against M.tuberculosis, it seems that carbomer does not affect the activity of pyrazinamide against ~M.tuberculosis ; pyrazinamide gel which contains carbomer is a safe therapeutic treatment in bronchial interventional therapy.

关 键 词：吡嗪酰胺 凝胶剂 抗结核药 介入 安全性 

分 类 号：R978.3[医药卫生—药品]